Oppenheimer Starts Palvella Therapeutics (PVLA) at Outperform, PT $85

September 9, 2025 6:04 AM EDT Send to a Friend
Oppenheimer analyst Trevor Allred initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Outperform rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login